293GilmartinGSLynchMTamisierRWeissJW
Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jrgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clment K, Dor J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, Bork P, Wang J, Ehrlich SD, Pedersen O, MetaHIT consortium
aseptic laboratory technique is required
Participants in the phase 2 trial lost an average of 7 kg (15 lbs) after 16 weeks, significantly more than the placebo group
Runners with this condition typically experience pain directly at the back of the heel, often accompanied by bony prominence or calcification
An oral dose must first pass through the digestive system and be absorbed, which can affect the timing and peak concentration